Publications
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn’s Disease: Systematic Review and Meta-Analysis
Citation
Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, Sands BE, Panaccione R, Narula N, Feagan BG, Singh S, Jairath V, Ma C. Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis. Dig Dis Sci. 2023 Sep;68(9):3702-3713. doi: 10.1007/s10620-023-08014-z. Epub 2023 Jun 28. PMID: 37378711.
Abstract
Background: Targeting interleukin-23 (IL-23) is an important therapeutic strategy for Crohn’s disease (CD).
Aims: This systematic review and meta-analysis assessed the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD.
